Niagen Bioscience, Inc. reported $129.4M in revenue and $17.4M in net income for fiscal 2025. See the full NAGE financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

[EFFECT] Niagen Bioscience, Inc. SEC Filing

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

EFFECT

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 07/10/2026 - 06:05 AM Accepted by SEC EDGAR 07/10/2026 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	July 9, 2026 4:05 P.M.

Form:

S-3

CIK:	0001386570
Company Name:	Niagen Bioscience, Inc.
File Number:	333-297093

Source: View Original Filing on SEC EDGAR